Editas Medicine, Inc.
NASDAQ: EDIT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gilmore O'Neill
- Employees
- 87
- Headquarters
- Cambridge, United States
- IPO year
- 2016
- Market cap
- $274.1M
- Website
- https://www.editasmedicine.com
Loading EDIT…
Loading profile data…Frequently asked questions about EDIT
What does Editas Medicine, Inc. (EDIT) do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulat...
Where does EDIT trade?
Editas Medicine, Inc. (EDIT) trades on the NASDAQ.
What sector is EDIT in?
Editas Medicine, Inc. (EDIT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Editas Medicine, Inc.?
Gilmore O'Neill is the chief executive officer of Editas Medicine, Inc. (EDIT).
Where is Editas Medicine, Inc. headquartered?
Editas Medicine, Inc. is headquartered in United States.
Does EDIT pay a dividend?
Editas Medicine, Inc. (EDIT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EDIT go public?
Editas Medicine, Inc. (EDIT) completed its initial public offering in 2016.